标题
Dissecting the biological heterogeneity of HER2-positive breast cancer
作者
关键词
HER2, Breast cancer, Intrinsic subtypes, HER2-enriched, PAM50, TILs
出版物
BREAST
Volume 59, Issue -, Pages 339-350
出版商
Elsevier BV
发表日期
2021-08-05
DOI
10.1016/j.breast.2021.07.019
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600E/K mutated malignant melanomas
- (2021) Sebastian Klein et al. Scientific Reports
- Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
- (2021) Francesco Schettini et al. npj Breast Cancer
- Gene expression profiles of breast cancer metastasis according to organ site
- (2021) Fara Brasó‐Maristany et al. Molecular Oncology
- HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
- (2021) Elisa Agostinetto et al. Cancers
- HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
- (2020) Francesco Schettini et al. CANCER TREATMENT REVIEWS
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
- (2020) Sandra M Swain et al. LANCET ONCOLOGY
- ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
- (2020) Gaia Griguolo et al. Cancers
- Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
- (2020) Leisha A Emens et al. LANCET ONCOLOGY
- Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
- (2020) Rilan Bai et al. Biomarker Research
- Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
- (2019) Joaquín Gavilá et al. BMC Medicine
- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
- (2019) Sherene Loi et al. LANCET ONCOLOGY
- HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
- (2019) Gabriel Rinnerthaler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial
- (2019) R Barroso-Sousa et al. ANNALS OF ONCOLOGY
- De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study
- (2019) V Guarneri et al. ANNALS OF ONCOLOGY
- Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial
- (2019) Matteo Lambertini et al. BREAST CANCER RESEARCH AND TREATMENT
- PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.
- (2019) Pier Franco Conte et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
- (2019) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era
- (2019) Gerald P. Linette et al. Current Hematologic Malignancy Reports
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- (2019) Udai Banerji et al. LANCET ONCOLOGY
- NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
- (2019) Louis Fehrenbacher et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
- (2019) Lillian M. Smyth et al. Cancer Discovery
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
- (2018) Michail Ignatiadis et al. JNCI-Journal of the National Cancer Institute
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
- (2018) Shixiang Wang et al. ONCOGENE
- Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
- (2018) Michail Ignatiadis et al. JNCI-Journal of the National Cancer Institute
- 190PDResearch-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies
- (2018) G Bianchini et al. ANNALS OF ONCOLOGY
- The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?
- (2018) Giuseppe Buono et al. Anti-Cancer Agents in Medicinal Chemistry
- Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
- (2018) Sarah Croessmann et al. CLINICAL CANCER RESEARCH
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
- (2018) Emiliano Cocco et al. Science Signaling
- Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2017) Fei Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
- (2017) Antonio Llombart-Cussac et al. LANCET ONCOLOGY
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
- (2017) Carlos R. Gil Del Alcazar et al. Cancer Discovery
- RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy
- (2017) Debora Fumagalli et al. JAMA Oncology
- A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
- (2017) Anne-Sophie Hamy et al. PLoS One
- PIK3CAmutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
- (2016) S. Loibl et al. ANNALS OF ONCOLOGY
- Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial
- (2016) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going
- (2016) Francesco Schettini et al. CANCER TREATMENT REVIEWS
- Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
- (2016) J. Baselga et al. CLINICAL CANCER RESEARCH
- Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients
- (2016) Giancarlo Pruneri et al. CURRENT OPINION IN ONCOLOGY
- Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
- (2016) Fabrice André et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
- (2016) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial
- (2016) Edith A. Perez et al. JNCI-Journal of the National Cancer Institute
- Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration
- (2016) Marcel Smid et al. Nature Communications
- “Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome
- (2016) Patrizia Vici et al. Oncotarget
- Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
- (2016) Celine Lefebvre et al. PLOS MEDICINE
- Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial
- (2016) Edith A. Perez et al. JNCI-Journal of the National Cancer Institute
- Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
- (2016) Edith A. Perez et al. JAMA Oncology
- Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
- (2015) G. Bianchini et al. ANNALS OF ONCOLOGY
- Clinical implications of the intrinsic molecular subtypes of breast cancer
- (2015) Aleix Prat et al. BREAST
- Prognostic and predictive immune gene signatures in breast cancer
- (2015) Davide Bedognetti et al. CURRENT OPINION IN ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
- (2014) A. Prat et al. CLINICAL CANCER RESEARCH
- Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
- (2014) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
- (2014) Aleix Prat et al. JNCI-Journal of the National Cancer Institute
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- The immune system and response to HER2-targeted treatment in breast cancer
- (2014) Giampaolo Bianchini et al. LANCET ONCOLOGY
- Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006
- (2013) Mothaffar F. Rimawi et al. JOURNAL OF CLINICAL ONCOLOGY
- Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31
- (2013) Katherine L. Pogue-Geile et al. JNCI-Journal of the National Cancer Institute
- Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer
- (2013) Sherene Loi et al. JNCI-Journal of the National Cancer Institute
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Tumor-infiltrating follicular helper T cells: The new kids on the block
- (2013) Chunyan Gu-Trantien et al. OncoImmunology
- Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer
- (2012) F. Andre et al. CLINICAL CANCER RESEARCH
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Practical implications of gene-expression-based assays for breast oncologists
- (2011) Aleix Prat et al. Nature Reviews Clinical Oncology
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differentiation of Effector CD4 T Cell Populations
- (2010) Jinfang Zhu et al. Annual Review of Immunology
- Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US
- (2010) Kathleen A. Cronin et al. CANCER INVESTIGATION
- Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
- (2010) L. Zitvogel et al. CLINICAL CANCER RESEARCH
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
- (2008) M. Untch et al. ANNALS OF ONCOLOGY
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
- (2008) Amancio Carnero et al. CURRENT CANCER DRUG TARGETS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started